CisplatinEtoposideAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsAntineoplastic Agents, PhytogenicDrug Administration ScheduleIfosfamideDoxorubicinLung NeoplasmsCarcinoma, Small CellCarboplatinCombined Modality TherapyDrug Resistance, NeoplasmTopoisomerase II InhibitorsPlatinumVincristineTreatment OutcomeCyclophosphamidePodophyllotoxinBleomycinInfusions, IntravenousDNA Topoisomerases, Type IIVinblastinePaclitaxelLeukopeniaApoptosisSurvival AnalysisOvarian NeoplasmsGerminomaCell Line, TumorTesticular NeoplasmsDisease-Free SurvivalCamptothecinAdministration, OralTumor Cells, CulturedDrug SynergismDNA DamageDeoxycytidineFluorouracilDrug EvaluationSurvival RateDrug Screening Assays, AntitumorNeoplasms, Germ Cell and EmbryonalDose-Response Relationship, DrugNeutropeniaAmsacrineDNA AdductsCytarabineCell SurvivalRemission InductionVomitingCarcinoma, Non-Small-Cell LungDrug ResistanceThrombocytopeniaHematologic DiseasesTeniposideTime FactorsNeoplasmsHead and Neck NeoplasmsCarmustineSalvage TherapyCarcinoma, Squamous CellNeoplasm StagingNauseaTaxoidsRadiotherapy DosageVindesineDose FractionationNucleic Acid Synthesis InhibitorsTransplantation, AutologousNeoplasm Recurrence, LocalMethotrexate